100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

OBJECTIVE: To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. BACKGROUND: Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) and has demonstrated efficacy in reducing migraine h...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Headache
मुख्य लेखकों: Rosen, Noah, Pearlman, Eric, Ruff, Dustin, Day, Kathleen, Jim Nagy, Abraham
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2018
विषय:
Research Submissions
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221112/
https://ncbi.nlm.nih.gov/pubmed/30341990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13427
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन